Abstract
Purpose
Transgender patients undergoing transitions often receive cross-sex hormonal therapies, placing them at uncertain risk for developing breast cancer. There is limited population-based information about the extent to which transgender patients undergo mammography screening. Our purpose was to determine the extent to which transgender patients undergo mammography screening using nationally representative survey data.
Methods
Transgender participants between ages 40–74 in the 2014 Behavioral Risk Factor Surveillance System survey were included. Proportions undergoing mammography screening in the last year or two years were calculated stratified by age category and transition status [male to female(MtF), female to male(FtM), non-conforming]. For each transition status, predictors of mammography screening were calculated using logistic regression.
Results
220 transgender patients were within 40–74 years old(35% were MtF, 51% were FtM, 14% were non-conforming). 60.0% underwent mammography screening within the last year (MtF—54.5%, FtM—64.3%, non-conforming—58.1%). 74.1% underwent screening within the last two years(MtF—70.1%, FtM—75.9%, non-conforming—77.4%). For all transgender patients, income category (OR 1.16, 0.82–1.64), higher education category (OR 1.09, 0.31–3.86) and health insurance (OR 0.38, 0.10–1.41) were not associated with increased adherence to mammography screening. Transgender patients were comparably likely to undergo mammography screening compared with non-transgender patients (Adjusted OR 0.97, 0.58–1.62).
Conclusions
High proportions of transgender survey respondents undergo mammography screening (57.9–66.1% within the last year, 71.9–74.4% within the last two years) in our sample, proportions comparable to non-transgender survey respondents.
Similar content being viewed by others
References
Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014
Deutsch MB, Buchholz D (2015) Electronic health records and transgender patients—practical recommendations for the collection of gender identity data. J Gen Intern Med 30(6):843–847
Bazzi AR, Whorms DS, King DS, Potter J (2015) Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health. 105(11):2356–2358
McPhee SJ, Nguyen TT, Shema SJ et al (2002) Validation of recall of breast and cervical cancer screening by women in an ethnically diverse population. Prev Med 35:463–473
Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M (2011) Injustice at every turn: a report of the national transgender discrimination survey. National Center for Transgender Equality and National Gay and Lesbian Task force, Washington, DC
Hubbard RA, O’Meara ES, Henderson LM et al (2016) Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S. Prev Med 89:169–177
Selvin E, Brett KM (2003) Breast and cervical cancer screening: sociodemographic predictors among white, black, and hispanic women. Am J Public Health 93(4):618–623
Travis RC, Key TJ (2003) Oestrogen exposure and breast cancer risk. Breast Cancer Res. 5(5):239–247
Unger CA (2016) Hormone therapy for transgender patients. Transl Androl Urol. 5(6):877–884
Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13(11):1141–1151
Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the women’s health initiative investigators. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. JAMA Oncol. 1(3):296–305
Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 10(12):3129–3134
Brown GR, Jones KT (2015) Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198
Makadon HJ, Mayer KH, Potter J, Goldhammer H (2015) Fenway guide to lesbian, gay, bisexual and transgender health, 2nd edn. American College of Physicians, Philadelphia
Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were obtained for the performance of this study.
Conflict of interest
Anand Narayan, Lizza Lebron-Zapata and Elizabeth Morris declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. IRB approval was not required as our study utilized publicly available information.
Rights and permissions
About this article
Cite this article
Narayan, A., Lebron-Zapata, L. & Morris, E. Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey. Breast Cancer Res Treat 166, 875–879 (2017). https://doi.org/10.1007/s10549-017-4461-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4461-8